Plasma Adiponectin Levels in Overweight and Obese Asians

Abstract

YANG, WEI-SHIUNG, WEI-JEI LEE, TOHRU FUNAHASHI, SACHIYO TANAKA, YUJI MATSUZAWA, CHIA-LING CHAO, CHI-LING CHEN, TONG-YUAN TAI, AND LEE-MING CHUANG. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002;10:1104 -1110. Objective: Hypoadiponectin has been documented in subjects with obesity, diabetes mellitus, or coronary heart disease, suggesting a potential use of plasma adiponectin in following the clinical progress in subjects with metabolic syndrome (MS). In this study, we investigated the plasma adiponectin levels in relation to the variables of MS among overweight/obese Asian subjects. Research Methods and Procedures:The plasma adiponectin, anthropometric and biochemical measurements, oral glucose tolerance tests (OGTT), and modified insulin suppression tests were performed on 180 overweight/obese Asian subjects [body mass index (BMI) Ն 23 kg/m 2 ], including 47 subjects with morbid obesity (BMI Ն 40 kg/m 2 ). Results: The plasma adiponectin levels negatively correlated with BMI, waist-to-hip ratio, fasting plasma glucose, insulin, triglyceride, uric acid levels, hyperinsulinemia, and glucose intolerance in OGTT, but positively with highdensity lipoprotein-cholesterol. In contrast, they were not related to blood pressure and total cholesterol. Moreover, insulin sensitivity, measured by quantitative insulin sensitivity check index (QUICKI) or in insulin suppression tests, significantly correlated with the plasma adiponectin levels. Among morbidly obese subjects, only the waist-to-hip ratio correlated with the plasma adiponectin levels. Using multivariate linear regression models, the area under curve of plasma glucose in OGTT and high-density lipoprotein-cholesterol among the overweight/obese subjects and WHR among the morbidly obese subjects were significantly related to the plasma adiponectin levels after adjustment for other variables. Discussion: In overweight/obese Asians, the plasma adiponectin levels significantly correlated with various indices of MS except hypertension. Whether the plasma adiponectin level could be a suitable biomarker for following the clinical progress of MS warrants further investigation.

The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives

“…22,23 This independent association was also observed among healthy subjects. 24 Chronic exposure to mild hyperuricemia may be a factor that contributes to microinflammation and hypoadiponectinemia in these individuals; however, an opposite explanation is under consideration.…”

Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes

“…On the other hand, there were strong consistent associations between adiponectin and plasma lipids, particularly plasma triglycerides (negative), HDL-C, Apo A1 and NEFA (positive). This strong association of adiponectin with HDL metabolism has been previously noted [40][41][42][43][44][45][46][47] and in fact in a study with 4500 subjects, it was proposed as a useful marker/risk factor in cardiovascular disease assessment. 40 While the physiological nature of this correlation has not been determined, this may be tied to the proposed functions of adiponectin at the vascular wall which include modulation of endothelial function, inhibition of vascular smooth muscle proliferation, suppression of macrophage transformation and modulation of inflammation (for a review, see Ukkola and Santaniem 22 ).…”

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

“…Adiponectin was also suggested to contribute to carcinogenesis in obesity-related cancers due to its effects on insulin resistance and direct action on tumor cells (Kelesidis et al, 2006;Dalamaga et al, 2012;Joshi and Lee, 2014). Reduced circulatory levels of adiponectin have been shown in obese patients and implicated in the development of obesity-related malignancy (Yang et al, 2002;Cnop et al, 2003). Low ApN levels were found in breast, endometrial, prostate, colon and gastric cancers (Mantzoros et al, 2004;Ishikawa et al, 2005;Michalakis et al, 2007;Kumor et al;2009;Gonullu et al, 2010;Chen et al, 2012;Gulcelik et al, 2012;Ho et al, 2012).…”